Paper - WANFANG MED ONLINE

You Position: Home > Paper

Advance in the effectiveness and safety of new oral anticoagulants in the antithrombotic treatment of atrial fibrillation combined with coronary atherosclerotic heart disease

( views:16, downloads:31 )

Author:: No author available

Journal Title:: China Medicine

Issue:: 2

DOI:: 10.3760/j.issn.1673-4777.2023.02.029

Key Word:: 心房颤动;冠心病(冠状动脉粥样硬化性心脏病);经皮冠状动脉介入;新型口服抗凝药

Abstract：心房颤动合并冠心病(冠状动脉粥样硬化性心脏病)抗栓治疗的选择一直是一个难题.在抗血小板的同时也需要抗凝治疗,选择抗栓治疗方案时,兼顾降低出血风险的同时又能取得最大的临床疗效是心房颤动合并冠心病抗栓治疗方案的关键.华法林作为心房颤动传统的抗凝药物,由于其自身的局限性,推动了新型口服抗凝药(NOAC)的兴起,在抗栓治疗中选择口服抗凝药有了新的选择和认识.然而NOAC在心房颤动合并冠心病患者中的临床疗效及安全性仍有一些争议.本文就NOAC应用于心房颤动合并冠心病患者抗栓治疗中的有效性及安全性作一综述.

Reference

[1]白龙,杨晓红,崔晓冉,等.急性冠脉综合征合并房颤患者PCI术后应用利伐沙班和氯吡格雷双联抗栓的效果研究[J].2020,(21).
[2]李庆勇,汤宝鹏,牛锁成,等.利伐沙班与达比加群治疗房颤合并急性冠脉综合征患者PCI后的有效性和安全性对比[J].2021,(1).
[3]马长生,郭雪原.冠心病合并心房颤动的抗栓治疗策略[J].2014,(5).
[4]Lobraico-Fernandez Jessika,Baksh Salma,Nemec Eric.Elderly Bleeding Risk of Direct Oral Anticoagulants in Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Cohort Studies[J].2019,19(3).
[5]van Rein, Nienke,Heide-Jorgensen, Uffe,Lijfering, Willem M.,etc.Major Bleeding Rates in Atrial Fibrillation Patients on Single, Dual, or Triple Antithrombotic Therapy Results From a Nationwide Danish Cohort Study[J].2019,139(6).
[6].Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease[J].2020,6(3).
[7]Lopes, Renato D.,Heizer, Gretchen,Aronson, Ronald,etc.Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation[J].2019,380(16).
[8]中华医学会心电生理和起搏分会,中国医师协会心律学专业委员会,中国房颤中心联盟心房颤动防治专家工作委员会.心房颤动：目前的认识和治疗建议（2021）[J].2022,26(1).
[9]Aguilar,E.,García-Díaz,A.M.,SánchezMu?oz-Torrero,J.F.,etc.Clinical outcome of stable outpatients with coronary, cerebrovascular or peripheral artery disease, and atrial fibrillation[J].2012,130(3).
[10]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.冠心病合并心房颤动患者抗栓管理中国专家共识[J].2020,48(7).
[11]Bhatt DL,Angiolillo DJ,Faxon DP,etc.Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective.[J].2011,106(4).
[12]Cannon, Christopher P.,Bhatt, Deepak L.,Oldgren, Jonas,etc.Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation[J].2017,377(16).
[13]Yasuda, Satoshi,Kaikita, Koichi,Akao, Masaharu,etc.Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease[J].2019,381(12).
[14]Shinya Goto,Deepak L. Bhatt,Joachim Rother.Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis[J].2008,156(5).
[15]Kirchhof, Paulus,Benussi, Stefano,Kotecha, Dipak,etc.2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J].2016,37(38).
[16].Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention An Updated Network Meta-analysis[J].2020,5(5).
[17]Ewelina, Michniewicz,El?bieta, Mlodawska,Paulina, Lopatowska,etc.Patients with atrial fibrillation and coronary artery disease - Double trouble.[J].2017,63(1).
[18]Hindricks, G..2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) (vol 42, pg 373, 2021)[J].2021,42(5).
[19]Alamneh, Endalkachew A.,Chalmers, Leanne,Bereznicki, Luke R..Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?[J].2016,16(3).
[20]Christian T Ruff,Robert P Giugliano,Eugene Braunwald,etc.Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.[J].2014,383(9921).
[21]Gibson, C. Michael,Mehran, Roxana,Bode, Christoph,etc.Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI[J].2016,375(25).
[22]Thomas A Zelniker,Christian T Ruff,Stephen D Wiviott,etc.Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48[J].2019,8(2).